Announcement PDF +61 (03) 9482 3940 157 Heidelberg Rd, Northcote, VIC 3070 www.renerve.com.au ASX Announcement 5 January 2026 ReNerve Limited 2026 General Meeting Results ReNerve Limited (ASX, "ReNerve" or "the Company"), advises that the General Meeting of Shareholders was held today at 10.00am (AEDT). In accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), the details of the Resolutions and the Proxies received in respect of each Resolution are set out in the attached summary. All Resolutions were passed. - ENDS - This announcement has been approved for release by the Company’s Board of Directors. For further information and enquiries, please contact: Dr Julian Chick CEO & Managing Director ReNerve Ltd +61 (03) 9482 3940 info@renerve.com.au Matthew Wright Investor & Media Relations NWR Communications +61 (0) 451 896 420 matt@nwrcommunications.com.au About ReNerve Limited (ASX:RNV) ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide. Proven Clinical Success ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives. 2 | P a g e Comprehensive Product Portfolio ReNerve is advancing a complete suite of nerve repair solutions: • NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery. • Deep Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases. • Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds. • NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends. • NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting. • NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve repairs. Market Leadership and Growth With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1 Vision and Values We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery. 1 Global Nerve Repair Biomaterials Market Research Report (2020 – 2031) Disclosure of Proxy Votes ReNerve Limited General Meeting Monday, 05 January 2026 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Proxy Votes Poll Results (if applicable) Results Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed FOR AGAINST ABSTAIN PROXY'S DISCRETION FOR AGAINST ABSTAIN OUTCOME 1 RATIFICATION OF PRIOR ISSUE OF 21,581,587 TRANCHE 1 PLACEMENT SHARES P 29,022,832 28,624,792 98.63% 250,000 0.86% 0 148,040 0.51% 39,749,220 99.37% 250,000 0.63% 0 Carried 2 APPROVAL TO ISSUE 5,085,080 TRANCHE 2 PLACEMENT SHARES P 29,022,832 28,624,792 98.63% 250,000 0.86% 0 148,040 0.51% 39,749,220 99.37% 250,000 0.63% 0 Carried 3 APPROVAL TO ISSUE 26,666,667 ONE FOR ONE FREE ATTACHING OPTIONS P 29,022,832 28,614,792 98.59% 260,000 0.90% 0 148,040 0.51% 39,739,220 99.35% 260,000 0.65% 0 Carried 4 APPROVAL TO ISSUE 4,000,000 LEAD MANAGER OPTIONS P 29,804,524 29,396,484 98.63% 264,790 0.89% 0 143,250 0.48% 40,516,122 99.35% 264,790 0.65% 0 Carried